Synthesis, Crystal Structure and Cytotoxicity of Ru(Ⅱ) Complex Targeting DNA

Shuang-Shuang GAI Jun-Feng LAN Peng ZHANG Cai-Yun JIANG Yi-Ming QIN

Citation:  Shuang-Shuang GAI, Jun-Feng LAN, Peng ZHANG, Cai-Yun JIANG, Yi-Ming QIN. Synthesis, Crystal Structure and Cytotoxicity of Ru(Ⅱ) Complex Targeting DNA[J]. Chinese Journal of Inorganic Chemistry, 2021, 37(7): 1277-1283. doi: 10.11862/CJIC.2021.151 shu

以DNA为靶点的钌(Ⅱ)配合物的合成、晶体结构和抗肿瘤活性

    通讯作者: 蒋才云, jiangcaiyun2013@163.com
    覃逸明, qym68@163.com
  • 基金项目:

    广西高校中青年教师科研基础能力提升项目 2019KY0853

    广西高校中青年教师科研基础能力提升项目 2020KY23016

摘要: 为开发新型钌(Ru)抗肿瘤药物,以3-甲基-2-噻吩甲醛-4-羟基苯甲酰肼席夫碱配体(L)合成了[Ru(L)(DMSO)2Cl2](1)(DMSO=二甲基亚砜)。用X射线单晶衍射法测定了1的晶体结构。配合物1的结构由1个Ru(Ⅱ)中心离子与2个DMSO分子、2个氯离子、1个L配位而成。通过MTT实验分析,1对T24细胞表现出良好的抗肿瘤活性。同时,通过彗星实验、蛋白质印迹实验和DNA琼脂糖凝胶电泳实验结果证明1可以有效结合DNA,诱导DNA损伤,最终杀死肿瘤细胞。导致DNA损伤的原因很可能是由于细胞与1孵育后细胞内可以产生大量的活性氧。

English

  • Cancer seriously endangers people′s life and safety. In 2018, the World Health Organization reported that cancer was the second leading cause of death, killing about 9.6 million people worldwide[1]. Chemotherapy is a major method widely applied in current clinical cancer treatment[2-3]. Cisplatin is one of the most effective chemotherapeutic drugs approved by the Food and Drug Administration[4]. However, cisplatin is limited in clinical use due to its severe side effects[5-7]. Therefore, a range of metal complexes have been designed and synthesized for the treatment of cancer[8-11], of which ruthenium complexes are the most promising to be the next generation of anticancer agents[12-13].

    Many Ru complexes, such as KP -1019 and NAMI-A, have been widely studied due to their excellent clinical efficacy[14-15]. Ru complexes have been applied in various fields of medicinal chemistry against tumors with different biological targets[16-17]. In addition, aroylhydrazones possess excellent biological and pharmaceutical activities, including anticancer, anti - inflammatory, and anti - tubercular activities[18]. More importantly, previous studies have been showed that anticancer activity of metal - base complexes derived from aroylhydrazones were higher than that of the ligands alone[19-20]. Hence, the design of aroylhydrazone complexes chelated with ruthenium ion for anticancer treatment has an important prospect.

    The primary target of metal - based agents to kill tumors is DNA, which causes amount of DNA lesions, thus preventing transcription and replication[21-22]. Considering the above factors, we designed and synthesized a Ru(Ⅱ) complex derived from aroylhydrazones (Scheme 1). Subsequently, the structure of Ru(Ⅱ) complex was measured via X-ray crystallography and solved. Finally, the anticancer activity of Ru(Ⅱ) complex and its effect on DNA were investigated in vitro.

    Scheme 1

    Scheme 1.  Synthetic route for [Ru(L)(DMSO)2Cl2] (1)

    The chemical reagents and solvent used were analytically pure and purchased from Sigma or Innochem Company. Tumor cell lines were supplied by the Shanghai institute for biochemistry and cell biology.

    A mixture of 0.1 mmol 4 - hydroxybenzhydrazide and 0.1 mmol 3-methyl-2-thiophenecarboxaldehyde were dissolved in 20 mL methanol and refluxed. Then the ligand L was obtained. Subsequently, 0.1 mmol RuCl3 and 50 μL DMSO (dimethyl sulfoxide) were added and stirred for another 2 h (Scheme 1). The resulting solution was evaporated at room temperature, and the yellow -brown crystals crystallized after about 7 d. The purity of complex 1 (>95%) was detected by HPLC (Fig. S1). Anal. Calcd. for C17H26Cl2N2O5RuS3(%): C, 33.66; H, 4.32; N, 4.62. Found(%): C, 33.72; H, 4.35; N, 4.58.

    A single crystal (0.18 mm×0.19 mm×0.22 mm) of 1 was picked out and then measured by a Bruker SMART Apex Ⅱ CCD diffractometer with graphite - monochromated Mo radiation (λ =0.071 073 nm). The diffraction data were collected. The structure was solved by direct methods and refined with the XL refinement package using least squares minimization by olex 2.0 software[23]. All non - hydrogen atoms were anisotropically refined. All hydrogen atoms were fixed in calculated positions and refined isotropically. The data is listed in Table 1, and selected bond lengths and angles are listed in Table 2.

    Table 1

    Table 1.  Crystal data and structure refinement for complex 1
    下载: 导出CSV
    Empirical formula C17H24Cl2N2O4RuS3·H2O Dc/(g·cm-3) 1.673
    Formula weight 606.55 μ/mm-1 1.163
    Crystal system Orthorhombic F(000) 2 464
    Space group Pbca Reflection collected 12 030
    a/nm 1.702 43(6) Independent reflection 4 241(Rint=0.033 8, Rσ=0.042 4)
    b/nm 1.595 86(7) Data, restraint, parameter 4 241, 0, 276
    c/nm 1.773 00(15) Goodness-of-fit on F2 1.149
    Volume/nm3 4.817 0(5) Final R indexes[I≥2σ(I)] R1=0.065 7, wR2=0.139 7
    Z 8 Final R indexes (all data) R1=0.098 5, wR2=0.163 4

    Table 2

    Table 2.  Selected bond lengths (nm) and angles (°) of complex 1
    下载: 导出CSV
    Ru1-S1 0.223 1(3) Ru1-Cl2 0.238 4(3) Ru1-N1 0.209 2(8)
    Ru1-Cl1 0.240 0(3) Ru1-O1 0.209 3(7) Ru1-S2 0.225 2(3)
     
    S1-Ru1-Cl1 91.87(12) O1-Ru1-Cl1 88.4(2) N1-Ru1-Cl2 84.8(3)
    S1-Ru1-Cl2 92.49(13) O1-Ru1-Cl2 86.7(2) N1-Ru1-O1 77.6(3)
    S1-Ru1-S2 93.21(10) O1-Ru1-S2 90.9(2) N1-Ru1-S2 168.5(2)
    Cl2-Ru1-Cl1 171.35(12) N1-Ru1-S1 98.2(2) S2-Ru1-Cl1 93.46(10)
    O1-Ru1-S1 175.8(2) N1-Ru1-Cl1 87.2(3) S2-Ru1-Cl2 93.75(12)

    CCDC: 2080249.

    The human balder cell lines T24 were cultured in 96-well plate and incubated with the selected concentrations of complex 1 for 48 h. Then the MTT (3-(4, 5-dimethylthiazol-2-yl)- 2, 5-diphenyltetrazolium bromide) solution was added to each well and incubated for 4 h. The medium was replaced with 100 μL DMSO. The absorbance was measured at an excitation wavelength of 570 or 630 nm with an enzyme-labelling instrument.

    The super-coiled plasmid pBR322 DNA was incu-bated with complex 1 for 4 h. Subsequently, agarose gel electrophoresis was employed to isolate pBR322 DNA in the reaction solution. These results were captured by camera for analyzing the ability of complex 1 to cleave DNA.

    T24 cells were co - incubated with Ru(Ⅱ) complex for 24 h, and then the cells were harvested and lysed to obtain the proteins. The concentrations of proteins were measured using BCA assay. The proteins were isolated by SDS-polyacrylamide gel, transferred to a PVDF (polyvinylidene fluoride) membrane and blocked with fat-free milk. Then, the membrane was incubated with primary antibodies and secondary antibodies respectively.

    Two millions T24 cells were placed into 10 cm dishes, and incubated with complex 1 for 24 h. T24 cells were collected by centrifugation and washed once time. Subsequently, DNA was extracted using a PureLink Genomic DNA Mini Kit (Invitrogen). DNA purity was detected by absorbance measurements at 260 and 280 nm. The DNA solution was added 1 mL of concentrated HNO3 and 0.5 mL of 30% H2O2. Finally, these samples were detected by ICP-MS.

    T24 cells were seeded into 10 cm dishes, and then incubated with complex 1. After 24 h, the cells were collected and washed. Subsequently, the cellular components were isolated and extracted according to the instructions of the mitochondrial isolation kit and the nuclear isolation kit, respectively. The samples were detected by ICP-MS.

    The binding mode of complex 1 in DNA (PDB ID: 1D64) was investigated using AutoDock 4.0. Target receptor (DNA) and complex 1 were prepared via docking protocol and saved into‘PDBQT ’format. And then the‘autogrid’and‘autodock’were performed, respectively. Energy-scoring function was used to ensure the best Ru(Ⅱ) complex-DNA pose.

    T24 cells were cultured into 6 - well plates, and treated with complex 1 for 24 h. After incubation, T24 cells were collected and stained in the dark with 2′, 7′- dichlorodihydro - fluorescein diacetate (H2DCF - DA) for 30 min. Intracellular ROS generation was detected by flow cytometry.

    T24 cells were incubated with complex 1 for 24 h, and the cells were harvested. 1×104 cells were embedded in 80 μL low -gelling-temperature agarose and rapidly pipetted onto a pre-coated microscope slide. These slides were electrophoresed for 20 min, and then stained with PI for 30 min in dark. Finally, the slides were graphed using a laser confocal microscope.

    X-ray diffraction analysis reveals that 1 crystalliz-es in the orthorhombic space group Pbca. As shown in Fig. 1, the structure of complex 1 is composed of a central Ru(Ⅱ)ion, two DMSO molecules, two chloride ions, and a Schiff base ligand L. The central Ru(Ⅱ) forms a six - coordinated environment, which is composed of one N atom (Ru1—N1 0.209 2 nm) and one O atom (Ru1—O1 0.209 3 nm) of HL, two S atoms (Ru1—S1 0.223 1 nm, Ru1—S2 0.225 2 nm) of DMSO and two Cl atoms (Ru1—Cl1 0.240 0 nm, Ru1—Cl2 0.238 4 nm).

    Figure 1

    Figure 1.  ORTEP diagram of complex 1 showing 30% probability level ellipsoids

    One crystalline water molecule is not shown

    The cytotoxicity of 1 against T24 cells was assessed using the MTT assay. The IC50 values of HL, RuCl3 and DMSO were greater than 50 μmol·L-1. These results indicate that the compounds do not exhibit significant antitumor activity. While the synthesized complex 1 from the ligand and RuCl3 exhibited remarkably activity (IC50=15.28 μmol·L-1), as shown in Fig. 2.

    Figure 2

    Figure 2.  Cytotoxicity of 1 at different concentrations

    The cellular uptake of 1 by T24 cells was measured using ICP-MS. As shown in Fig. 3, the contents of ruthenium in cells, nuclei and mitochondria after treatment of 1 were 1.23, 0.28 and 0.11 nmol, respectively. These results suggest that 1 can efficiently enter the cell and accumulate in the nucleus.

    Figure 3

    Figure 3.  ICP-MS analysis of total Ru contents in cytoplasm, mitochondria, and in nucleus of T24 cells (1×106 cells) treated with 1 for 24 h
    2.4.1   DNA cleavage

    DNA is the primary intracellular target of many PT/Ru drugs in the treatment of tumors[21-22]. Hence, the DNA-cleaving activity of 1 was investigated by an agarose gel electrophoresis assay using pBR322 DNA. The control group cannot cleave the PBR322 DNA, whereas 1 can efficiently relax the supercoiled form (Form Ⅰ) of pBR322 DNA into open circular form (Form Ⅱ) in a dose - dependent manner. These results strongly suggest that complex 1 has a strong effect on DNA (Fig. 4).

    Figure 4

    Figure 4.  Agarose gel electrophoresis patterns for cleavage of pBR322 DNA by 1
    2.4.2   Docking studies

    To better understand the mode between B - DNA and 1, molecular docking was carried out for studying the interactions. Complex 1 fitted well into the curved profile of the B-DNA in the minor groove located in the A-T rich region (Fig. 5). The energy minimization structure indicates that 1 is stabilized by hydrophobic contact, van der Waals forces and B - DNA functional groups.

    Figure 5

    Figure 5.  Molecular docked model of 1 with B-DNA
    2.4.3   DNA damage studies

    To further confirm the ability of 1 acting on DNA in tumor cells, the genomic DNA was extracted from T24 cells after treated with 1. The Ru content in the genomic DNA was at highly level, and the significantly elevated level of Ru content was in a dose - dependent fashion (Fig. 6).

    Figure 6

    Figure 6.  Amount of Ru in genomic DNA (1 μg) of T24 cells after treatment of 1

    T24 cells were induced apparent DNA damage co- incubated with complex 1, which was characterized by the tail DNA. The number and length of tail DNA were in positive correlation with the degree of DNA damage. The 1 - treated group produced more and longer tail DNA in a dose-dependent manner than the control group (Fig. 7).

    Figure 7

    Figure 7.  Comet assay for analyzing DNA damage of T24 cells after treatment of 1

    Tail DNA was marked with white arrow

    Western blotting assays showed that the expression level of γH2AX (a well - known marker for DNA double-strand breaks) in the control group was kept at lower levels, while that in the treatment group significantly increased (Fig. 8). Taken together, these results strongly indicate that direct interaction with DNA is a possible mechanism for complex 1 to play a role in killing tumor cells.

    Figure 8

    Figure 8.  Expression level of γH2AX treated with 1
    2.4.4   ROS generation

    Generally, ROS is, at least in part, responsible for the cleavage of DNA[24-26]. Therefore, the amount of intracellular ROS after treatment of 1 was investigated by flow cytometry using the DCFH-DA. T24 cells treated with 1 led to a shift in the fluorescence peak to the right compared to the un - treatment group, which indicate that 1 significantly increases intracellular ROS levels in a dose-dependent fashion (Fig. 9).

    Figure 9

    Figure 9.  Analysis of ROS levels in T24 cells treated with 1 for 24 h

    A Ru(Ⅱ) complex, [Ru(L)(DMSO)2Cl2] (1), was synthesized and its anticancer activity was investigated. Complex 1 exhibited effective activities against T24 cells, whereas the ligands had no significant cytotoxicity. Complex 1 is possible to kill tumor cells through the following mechanisms: 1 can bind to DNA bases, form DNA adducts, induce genomic DNA damage, and may block transcription and replication. Additionally, 1 can produce amount of ROS, causing oxidative loss of T24 cells, which leads to tumor cell death. In summary, complex 1 has potential as an anti-cancer chemotherapeutic agent. Our studies may be useful in guiding the development for designing new metal - base antitumor agents.


    Supporting information is available at http://www.wjhxxb.cn
    1. [1]

      El-Kordy E A. J. Microsc. Ultrastruct. , 2019, 7: 153-164 doi: 10.4103/JMAU.JMAU_21_19

    2. [2]

      Mukaya E H, Mbianda X Y. Mini-Rev. Med. Chem. , 2020, 20: 726-738 doi: 10.2174/1389557519666191107142926

    3. [3]

      Schweigert M, Dubecz A, Stein H J. Nat. Rev. Gastroenterol. Hepatol. , 2013, 10: 230-244 doi: 10.1038/nrgastro.2012.236

    4. [4]

      Rancoule C, Guy J B, Vallard A, Ben Mrad M, Rehailia A, Magné N. Bull. Cancer, 2017, 104: 167-176 doi: 10.1016/j.bulcan.2016.11.011

    5. [5]

      Rosenberg B, Van Camp L, Krigas T I. Nature, 1965, 205: 698-699 doi: 10.1038/205698a0

    6. [6]

      Rosenberg B, Van Camp L, Grimley E B, Thomson A J. J. Biol. Chem. , 1967, 242: 1347-1352 doi: 10.1016/S0021-9258(18)96186-7

    7. [7]

      Notaro A, Frei A, Rubbiani R, Jakubaszek M, Basu U, Koch S, Mari C, Dotou M, Blacque O, Gouyon J, Bedioui F, Rotthowe N, Winter R F, Goud B, Ferrari S, Tharaud M, Řezáčová M, Humajová J, Tomšík P, Gasser G. J. Med. Chem. , 2020, 63: 5568-5584 doi: 10.1021/acs.jmedchem.0c00431

    8. [8]

      Misirlic-Dencic S, Poljarevic J, Isakovic A M, Sabo T, Markovic I, Trajkovic V. Curr. Med. Chem. , 2020, 27: 380-410 doi: 10.2174/0929867325666181031114306

    9. [9]

      Sun Y, Heidary D K, Zhang Z, Richards C I, Glazer E C. Mol. Pharm. , 2018, 15: 3404-3416 doi: 10.1021/acs.molpharmaceut.8b00407

    10. [10]

      Mudavath R, Vuradi R K, Bathini U, Narsimha N, Kunche S, Sunitha S N T, Ch S D. Nucleosides Nucleotides Nucleic Acids, 2019, 38: 874-900 doi: 10.1080/15257770.2019.1618470

    11. [11]

      Leskovac A, Petrovic S, Lazarevic-Pasti T, Krstic M, Vasic V. J. Biol. Inorg. Chem. , 2018, 23: 689-704 doi: 10.1007/s00775-018-1560-x

    12. [12]

      Biancalana L, Pampaloni G, Marchetti F. Chimia (Aarau), 2017, 71: 573-579 doi: 10.2533/chimia.2017.573

    13. [13]

      Alessio E, Messori L. Molecules, 2019, 24: 1995-2014 doi: 10.3390/molecules24101995

    14. [14]

      Trondl R, Heffeter P, Kowol C R, Jakupec M A, Berger W, Keppler B K. Chem. Sci. , 2014, 5: 2925-2932 doi: 10.1039/C3SC53243G

    15. [15]

      Nardon C, Brustolin L, Fregona D. Future Med. Chem. , 2016, 8: 211-226 doi: 10.4155/fmc.15.175

    16. [16]

      Notaro A, Gasser G. Chem. Soc. Rev. , 2017, 46: 7317-7337 doi: 10.1039/C7CS00356K

    17. [17]

      Hartinger C G, Jakupec M A, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson P J, Keppler B K. Chem. Biodivers. , 2008, 5: 2140-2155 doi: 10.1002/cbdv.200890195

    18. [18]

      Samanta B, Chakraborty J, Shit S, Batten S R, Jensen P, Masuda J D, Mitra S. Inorg. Chim. Acta, 2007, 360: 2471-2484 doi: 10.1016/j.ica.2006.12.019

    19. [19]

      Deng J G, Gou Y, Chen W. Fu X, Deng H. Bioorg. Med. Chem. , 2016, 24: 2190-2198 doi: 10.1016/j.bmc.2016.03.033

    20. [20]

      Monfared H H, Vahedpour M, Yeganeh M M, Ghorbanloo M, Mayer P, Janiak C. Dalton. Trans. , 2011, 40: 1286-1294 doi: 10.1039/c0dt00371a

    21. [21]

      Rocha C R, Silva M M, Quinet A, Cabral-Neto J B, Menck C. Clinics (Sao Paulo), 2018, 73: 478-488

    22. [22]

      Rodríguez-Corrales J Á, Wang J, Winkel B S J, Brewer K J. ChemBioChem, 2018, 19: 2216-2224 doi: 10.1002/cbic.201800369

    23. [23]

      Dolomanov O V, Bourhis L J, Gildea R J, Howard J A K, Puschmann H. J. Appl. Crystallogr. , 2009, 42: 339-341 doi: 10.1107/S0021889808042726

    24. [24]

      Celik H, Arinç E. J. Pharm. Pharm. Sci. , 2008, 11: 68-82

    25. [25]

      Pracharova J, Radosova M T, Dvorak T E, Thangappan R, Arivanandhan M. Dalton. Trans. , 2016, 45: 13179-13186 doi: 10.1039/C6DT01467D

    26. [26]

      Wani T H, Chakrabarty A, Shibata N, Yamazaki H, Guengerich F P, Chowdhury G. Chem. Res. Toxicol. , 2017, 30: 1622-1628 doi: 10.1021/acs.chemrestox.7b00127

  • Scheme 1  Synthetic route for [Ru(L)(DMSO)2Cl2] (1)

    Figure 1  ORTEP diagram of complex 1 showing 30% probability level ellipsoids

    One crystalline water molecule is not shown

    Figure 2  Cytotoxicity of 1 at different concentrations

    Figure 3  ICP-MS analysis of total Ru contents in cytoplasm, mitochondria, and in nucleus of T24 cells (1×106 cells) treated with 1 for 24 h

    Figure 4  Agarose gel electrophoresis patterns for cleavage of pBR322 DNA by 1

    Figure 5  Molecular docked model of 1 with B-DNA

    Figure 6  Amount of Ru in genomic DNA (1 μg) of T24 cells after treatment of 1

    Figure 7  Comet assay for analyzing DNA damage of T24 cells after treatment of 1

    Tail DNA was marked with white arrow

    Figure 8  Expression level of γH2AX treated with 1

    Figure 9  Analysis of ROS levels in T24 cells treated with 1 for 24 h

    Table 1.  Crystal data and structure refinement for complex 1

    Empirical formula C17H24Cl2N2O4RuS3·H2O Dc/(g·cm-3) 1.673
    Formula weight 606.55 μ/mm-1 1.163
    Crystal system Orthorhombic F(000) 2 464
    Space group Pbca Reflection collected 12 030
    a/nm 1.702 43(6) Independent reflection 4 241(Rint=0.033 8, Rσ=0.042 4)
    b/nm 1.595 86(7) Data, restraint, parameter 4 241, 0, 276
    c/nm 1.773 00(15) Goodness-of-fit on F2 1.149
    Volume/nm3 4.817 0(5) Final R indexes[I≥2σ(I)] R1=0.065 7, wR2=0.139 7
    Z 8 Final R indexes (all data) R1=0.098 5, wR2=0.163 4
    下载: 导出CSV

    Table 2.  Selected bond lengths (nm) and angles (°) of complex 1

    Ru1-S1 0.223 1(3) Ru1-Cl2 0.238 4(3) Ru1-N1 0.209 2(8)
    Ru1-Cl1 0.240 0(3) Ru1-O1 0.209 3(7) Ru1-S2 0.225 2(3)
     
    S1-Ru1-Cl1 91.87(12) O1-Ru1-Cl1 88.4(2) N1-Ru1-Cl2 84.8(3)
    S1-Ru1-Cl2 92.49(13) O1-Ru1-Cl2 86.7(2) N1-Ru1-O1 77.6(3)
    S1-Ru1-S2 93.21(10) O1-Ru1-S2 90.9(2) N1-Ru1-S2 168.5(2)
    Cl2-Ru1-Cl1 171.35(12) N1-Ru1-S1 98.2(2) S2-Ru1-Cl1 93.46(10)
    O1-Ru1-S1 175.8(2) N1-Ru1-Cl1 87.2(3) S2-Ru1-Cl2 93.75(12)
    下载: 导出CSV
  • 加载中
计量
  • PDF下载量:  2
  • 文章访问数:  1062
  • HTML全文浏览量:  272
文章相关
  • 发布日期:  2021-07-10
  • 收稿日期:  2020-12-15
  • 修回日期:  2021-04-29
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章